Navigation Links
Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
Date:6/28/2009

reatment in Patients with Partial-Onset Seizures: Pooled Analysis of Three Double-Blind Phase III Clinical Studies. Poster presented at the American Epilepsy Society (AES) Congress, 5-9 December 2008, Seattle, WA, USA (Epilepsia, 49(Suppl. 7), 1-498, 2008).

6. WHO Atlas: Epilepsy Care in the World. WHO 2005

7. Mei PA, Montenegro MA, Guerreiro MM, Guerreiro CA. Pharmacovigilance in epileptic patients using antiepileptic drugs. Arq Neuropsiquiatr 2006 Jun;64(2A): 198-201. Epub 2006 Jun 9

8. Cramer J, Elger C, Halász P et al. An Evaluation of Quality of Life and Depressive Symptoms During Long-Term Treatment with Eslicarbazepine Acetate: BIA-2093-301 Study.QOL 301. Poster presented at the American Epilepsy Society (AES) Congress, 5-9 December 2009, Seattle, WA, USA (Epilepsia, 49(Suppl. 7), 1-498, 2008).

    For further information please contact
    Media contacts
    For more information please contact:
    BIAL (head office)
    Francisco Osório
    Tel.: +351-22-986-6100
    Mobile: +351-96-346-9968
    francisco.osorio@bial.com

    Pat Pearson
    Red Health
    Tel.: +44-207-025-6572
    Mobile: +44-7734406688
    par.pearson@redconsultancy.com



'/>"/>
SOURCE BIAL
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
2. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
3. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
4. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
5. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
6. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
9. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
10. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
11. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...anitoba, Nov. 6 With his proposed ...s set his sights on cutting name-brand prescriptio...ho fall into the "Part D" coverage gap, universall...bout the potential cost-cutting and feel it,s a pr...he most powerful lobbyists want a revised program ...
(Date:11/6/2009)...IANGLE PARK, N.C., Nov. 6 Chimerix...ly-available antiviral therapeutics to address lif...evelopment of the company,s lead antiviral compoun...and the Global Health Security Initiative (GHSI). ...developed for the treatment of smallpox, as well a...
(Date:11/6/2009)...Nov. 6 NexBio Inc., in collaborati...rol and Prevention (CDC), St. Louis University, an... publication of two articles in the peer-reviewed ...gest that DAS181 (Fludase ® ) may play a pote...ntion of the Pandemic Influenza A(H1N1) and drug-r...
Breaking Medicine Technology:Obama Healthcare Reforms Fall Short, but Betterthanmedicare.com Closes the 'Donut Hole' 2Obama Healthcare Reforms Fall Short, but Betterthanmedicare.com Closes the 'Donut Hole' 3Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 2Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 3NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 2NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 3NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 4Michael J Fox Foundation Awards 243 8 Million To Drive Nine Industry Partnerships For Pre Clinical Parkinsons Drug Development 52311 1Michael J Fox Foundation Awards 243 8 Million To Drive Nine Industry Partnerships For Pre Clinical Parkinsons Drug Development 52311 2Michael J Fox Foundation Awards 243 8 Million To Drive Nine Industry Partnerships For Pre Clinical Parkinsons Drug Development 52311 3Studies Show Genetic Activity of Antioxidants 52308 1Studies Show Genetic Activity of Antioxidants 52308 2Studies Show Genetic Activity of Antioxidants 52308 3Winners of the C Everett Koop Health Project Award Announced 52305 1Winners of the C Everett Koop Health Project Award Announced 52305 2
...ging Results for a Potential New Front-Line Treatm...AMBRIDGE, Mass., June 2 Genzyme Corp.,(Nasdaq: G...-enrolled,pivotal, phase 2 study examining the saf...s a single agent in previously untreated, older ad... who are unlikely to benefit,from conventional "7+...
...esponse Trends Suggest Improved Efficacy with High... - Dose Escalation Ongoing -, SAN ...sdaq: MDVN ) today announced that data from an on...vel androgen receptor antagonist,MDV3100, showed e...ining,serum levels of prostate specific antigen (P...
Other Medicine Technology:Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 3Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 4Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 5Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 6Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 7Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 8Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting 2Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting 3Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting 4
(Date:11/7/2009)...id A. Cook (GA), Louis J. Goodman (TX), Palmer P. ...ICAGO, Nov. 7 The Ameri... medical society executive leaders with achievemen... and ideals of the medical profession. The awards ...ing meeting in Houston. ,, (Logo: http://www...
(Date:11/7/2009)...USNewswire/ -- The U.S. bishops November 7 urged m... the Stupak-Ellsworth Amendment to the health care...Dahlkemper-Lipinski-Smith Amendment will keep in p...onscience protections in the Affordable Health Car...he letter was signed by Cardinal Justin Rigali, ch...
(Date:11/7/2009)...roblem across the U.S. , , SATURDAY, Nov. ...our-year colleges do it regularly (and, it,s not s... or more alcoholic drinks at a sitting. , "People ...aid Jenny Hwang, associate dean of students and di...versity on Long Island, N.Y. In fact, she said, he...
(Date:11/6/2009)..., Nov. 6 /PRNewswire-FirstCall/ - Cardiome Pharma ...that it will report financial results for the thir...of Monday, November 9, 2009. Cardiome will hold a ...(6:00am Pacific) on that day to discuss the result...16-695-7806 or 888-789-9572 and reference conferen...
(Date:11/6/2009)...n (NYSE: CNC ) today announced that it will prese... next few weeks. ,, Next week, at the Credit Suiss...ovember 11-13, 2009, at the Arizona Biltmore Resor...ay, November 11th at 4:30 p.m. Mountain Time. Inve...ene,s presentation at: http://w.on24.com/r.htm?e...
Breaking Medicine News(10 mins):Health News:AMA Honors Medical Society Executives 2Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 2Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 3Health News:Cardiome to Release Third Quarter Results 2Health News:Cardiome to Release Third Quarter Results 3Health News:Centene Corporation to Present at Upcoming Healthcare Conferences 2
...ony Ohotto, a physician,with Signature Hospice, ha...ttoo. "Limited life expectancy is no reason not to...e wrote the order as a health clearance, a,stateme... emotional decline in their young patient with a n...
...Long-Time Twin Cities Health Care ...rk G. Mishek, a Minnesota native,with extensive ex... Monday,as President and CEO of Hazelden, the nati...o: http://www.newscom.com/cgi-bin/prnh/20080825/A...
...ecting the expanding,scope of chronic disease care...environmental factors on health care systems and p...blisher Mary Ann Liebert Inc. have renamed,the pee... (Volume 11, Number 4). With the new name comes a,...
...n with certain genotype more affected, study finds...reast-feeding moms who take medicines containing c...eir infant, new Canadian research suggests. , The ... -- possibly harming the infant,s central nervous ...
...ases the risk of developing cancers of the respira...ysis, which the authors say is the first prospecti...rs in the October 1, 2008 issue of CANCER, a pee...rning incensewhich is made of plant materials mixe...
...enefit Group, LLC announces iCan Insurance, LLC (&...w offering major medical health plans from Avalon ...aton, FL (PRWEB) August 24, 2008 -- iCan Benefit G...re, Inc. http://www.icanbenefit.com/majorMedical/...
Other Medicine News:Health News:Signature Hospice Team Grants Patient's Unusual Wish 2Health News:Mark G. Mishek Is New President and CEO of Hazelden 2Health News:Disease Management Journal Changes Name and Expands Focus to Population Health Management 2Health News:Taking Codeine While Breast-Feeding May Harm Infant 2Health News:Taking Codeine While Breast-Feeding May Harm Infant 3Health News:Burning incense increases risk of respiratory tract cancers 2Health News:iCan Benefit Group, LLC Announces: Major Medical Division Now Offers Avalon Healthcare Products 2
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
Medicine Products: